Industry News

Agilent Technologies Inc. today enhanced its line of scientific instruments with two new models of the company's 7000 Series Triple Quadrupole Gas Chromatography/Mass Spectrometry systems. Agilent is showcasing the new quadrupole GC/MS/MS instruments-along with a new analyzer for pesticides and environmental pollutants-at the North American Chemical Residue Workshop, a four-day..."/>
Agilent Technologies Showcases Unprecedented Sensitivity and Ease of Use in New Triple Quadrupole GC/MS Instruments
Antibe Therapeutics Inc., a commercial-stage pharmaceutical growth company, is pleased to announce the appointment of Yung Wu to its Board of Directors. “We’ re delighted by the addition of Yung to our Board of Directors. We see many growth opportunities ahead for Antibe and we will benefit from Yung’ s unique insights and perspectives as we work to unlock the full potential of the Company,” said Walt Macnee, Antibe’ s Chair of the Board.“ We look forward to continuing a long-term..."/>
Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
Incyte Corporation announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology Annual Congress 2016, taking place in Copenhagen, Denmark from October 7-11, 2016. The ECHO-202 study is..."/>
Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates, today announced that the U.S. Food and Drug Administration granted Fast Track designation for Cerulean’ s lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer. “We appreciate the FDA’ s acknowledgement of CRLX101’ s potential in an area of..."/>
Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer
Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the enrollment of the first patient in Japan by SymBio Pharmaceuticals in the global Phase 3 INSPIRE trial, investigating IV rigosertib as a treatment for higher-risk myelodysplastic syndromes following failure of hypomethylating agent therapy. SymBio licensed rights to..."/>
Onconova Announces Enrollment of First Patient in Japan by SymBio
Ionis Pharmaceuticals, Inc. announced today that it has earned $10 million from Janssen Biotech, Inc. upon licensing IONIS-JBI1-2.5 Rx, an orally delivered antisense drug designed to locally inhibit an undisclosed target in the gastrointestinal tract for the treatment of a GI autoimmune disease. Janssen will assume all global development, regulatory and commercialization responsibilities for IONIS-JBI1-2.5 Rx once Ionis..."/>
Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen
ProMIS Neurosciences, a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, implicated in the development of Amyotrophic Lateral Sclerosis and frontotemporal dementia. "ProMIS will apply its proprietary computational algorithms, supplemented by other methods..."/>
ProMIS Neurosciences announces new program to identify novel ALS disease targets on toxic strains of protein TDP43
Shire plc, following its combination with Baxalta in June, will affirm its commitment to advancing patient care and scientific innovation at the International Congress of the World Federation of Hemophilia in Orlando, Florida, July 24-28, 2016. Data at the Congress this year will showcase the company's robust hematology portfolio and pipeline."/>
Shire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of the World Federation of Hemophilia
Celgene to receive options to jointly develop and commercialize Jounce’ s lead product candidate, JTX-2011, and additional innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages. CAMBRIDGE, Mass., July 19, 2016-- Jounce Therapeutics,..."/>
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer
RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it will report its financial results for the second quarter of 2016 on Tuesday, July 26, 2016.. The Company will also host a conference call on Tuesday, July 26, 2016, at..."/>
RedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016
Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage’ s Board of Directors. “The Sage team is excited to welcome Mr. Germano to our Board,” said Jeff Jonas, M.D., Chief Executive Officer of Sage.“ Mr."/>
Sage Appoints Geno Germano to Company's Board of Directors
Cytori Therapeutics, Inc. announced today the publication of the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to dental implantation. The publication reported approximately 42% greater bone formation in maxillary sinus floor elevation procedures treated with cells in combination with scaffolds versus those that received scaffold alone. The study, conducted by..."/>
Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration
Navidea Biopharmaceuticals, Inc. announced that it has received Institutional Review Board approval from the University of California, San Francisco School of Medicine for a clinical study examining the ability of Lymphoseek ® injection, a Manocept™ platform product, to specifically identify active rheumatoid arthritis in pre-identified RA-affected joints. The study will begin enrolling patients shortly. Additionally, Navidea has received WIRB IRB..."/>
Navidea Receives IRB Approval for its Lymphoseek® Rheumatoid Arthritis Clinical Trial Protocol
CytoDyn Inc., a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, announces that it has submitted a new protocol to the FDA for treatment naïve patients under its current open IND. This is a two-week Phase 2 b, randomized, double-blind, placebo-controlled, multi-center study to assess safety and efficacy of PRO 140 in treatment-naïve adults with HIV-1..."/>
CytoDyn Submits Protocol for Phase 2b Trial for Treatment Naïve HIV Patients
Capital Senior Living Corporation will host a conference call with senior management to discuss the Company’ s second quarter 2016 financial results. The call will be held on Tuesday, August 2, 2016, at 5:00 p.m. Eastern Time. The Company’ s earnings announcement is scheduled to be released to news services after the market closes on Tuesday, August 2, 2016.."/>
Capital Senior Living Corporation Announces Release Date for Second Quarter 2016 Financial Results
SciClone Pharmaceuticals, Inc. today provided an update on part of the strategic review process that was previously announced in February 2016. The Company announced that it is no longer continuing active discussions with potential acquirers which were undertaken as part of its strategic review process, and plans to remain an independent publicly traded company as it continues to execute on its strategic growth plan for its core..."/>
SciClone Provides Update On Strategic Review Process
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the issuance of two patents by the U.S. Patent and Trademark Office for Egalet's proprietary Guardian™ Technology. U.S. patent number 9,358,295 covers through 2031 immediate-release formulations intended to be resistant to abuse by intake of..."/>
Egalet Announces Issuance of Two New U.S. Patents for Guardian™ Technology
ACETO Corporation revealed on Monday that it has appointed Walter J. Kaczmarek III as its chief operating officer. Effective 1 August 2016, Kaczmarek will oversee, lead and manage the company's day-to-day operations at three business segments, reporting to CEO Salvatore Guccione,. Most recently, Kaczmarek has worked as president, Multisource Pharmaceutical Division at Mallinckrodt Pharmaceuticals."/>
ACETO elects Walter Kaczmarek III COO
UnitedHealth Group reported second quarter results..."/>
UnitedHealth Group Reports Second Quarter Results
Oculus Innovative Sciences, Inc., today announced that the financial results for its fiscal first quarter 2017, ended June 30, 2016, will be released after the U.S. markets close on July 28, 2016. The earnings release will be followed by a conference call at 1:30 p.m. PDT on July 28, 2016, to discuss fiscal first quarter results.. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or..."/>
Oculus Innovative Sciences Announces Fiscal First Quarter 2017 Financial Results and Conference Call

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials850 Articles
Information Technology745 Articles
Consumer Discretionary696 Articles
Industrials541 Articles
Health Care465 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at